Evidence map›Paper›PMID 33596880›Full record

ArticleBMC public health2021

Female breast cancer in New South Wales, Australia, by country of birth: implications for health-service delivery.

David Roder, George W Zhao, Sheetal Challam, Alana Little, Elisabeth Elder, Gordana Kostadinovska, Lisa Woodland, David Currow

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

David RoderCancer Information and Analysis, Cancer Institute New South Wales, Level 4, 1 Reserve Road, St Leonards NSW 2065, PO Box 41, Alexandria, NSW, 1435, Australia. david.roder@unisa.edu.au.ORCID 0000-0001-6442-4409
George W ZhaoCancer Information and Analysis, Cancer Institute New South Wales, Level 4, 1 Reserve Road, St Leonards NSW 2065, PO Box 41, Alexandria, NSW, 1435, Australia.
Sheetal ChallamEquity, Multicultural Program, Cancer Institute New South Wales, St Leonards, NSW, Australia.
Alana LittleCancer Information and Analysis, Cancer Institute New South Wales, Level 4, 1 Reserve Road, St Leonards NSW 2065, PO Box 41, Alexandria, NSW, 1435, Australia.
Elisabeth ElderSpecialist Breast Surgery, Westmead Breast Cancer Institute, Westmead, NSW, Australia.
Gordana KostadinovskaMulticultural Health Service, Nepean Blue Mountains Local Health District, Penrith, NSW, Australia.
Lisa WoodlandPriority Populations, South Eastern Sydney Local Health District, Sydney, NSW, Australia.
David CurrowCancer Institute New South Wales, St Leonards, NSW, Australia.
Cancer Institute of New South Wales · AUSouth Eastern Sydney Local Health District · AU

Funding

National Breast Cancer Foundation CRP-17-001
6 · The paper itself

Abstract

backgroundNSW has a multicultural population with increasing migration from South East Asia, the Western Pacific and Eastern Mediterranean.

objectiveTo compare cancer stage, treatment (first 12 months) and survival for 12 country of birth (COB) categories recorded on the population-based NSW Cancer Registry.

designHistoric cohort study of invasive breast cancers diagnosed in 2003-2016. PATIENTS: Data for 48,909 women (18+ ages) analysed using linked cancer registry, hospital inpatient and Medicare and pharmaceutical benefits claims data. MEASUREMENT: Comparisons by COB using multivariate logistic regression and proportional hazards regression with follow-up of vital status to April 30th, 2020.

resultsCompared with the Australia-born, women born in China, the Philippines, Vietnam and Lebanon were younger at diagnosis, whereas those from the United Kingdom, Germany, Italy and Greece were older. Women born in China, the Philippines, Vietnam, Greece and Italy lived in less advantaged areas. Adjusted analyses indicated that: (1) stage at diagnosis was less localised for women born in Germany, Greece, Italy and Lebanon; (2) a lower proportion reported comorbidity for those born in China, the Philippines and Vietnam; (3) surgery type varied, with mastectomy more likely for women born in China, the Philippines and Vietnam, and less likely for women born in Italy, Greece and Lebanon; (4) radiotherapy was more likely where breast conserving surgery was more common (Greece, Italy, and Lebanon) and the United Kingdom; and (5) systemic drug therapy was less common for women born in China and Germany. Five-year survival in NSW was high by international standards and increasing. Adjusted analyses indicate that, compared with the Australian born, survival from death from cancer at 5 years from diagnosis was higher for women born in China, the Philippines, Vietnam, Italy, the United Kingdom and Greece.

conclusionsThere is diversity by COB of stage, treatment and survival. Reasons for survival differences may include cultural factors and healthier migrant populations with lower comorbidity, and potentially, less complete death recording in Australia if some women return to their birth countries for treatment and end-of-life care. More research is needed to explore the cultural and clinical factors that health services need to accommodate.

Indexed as

Breast NeoplasmsAgedAustraliaChinaCohort StudiesFemaleGermanyGreeceHumansItalyLebanonMastectomyNational Health ProgramsNew South WalesPhilippinesUnited KingdomBirth countriesBreast cancer survivalNew South Wales

Identifiers

PMID33596880
PMCPMC7890625
OpenAlexW3131212908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.